Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]-Brensocatib in Healthy Males
NCT05652257Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Aug 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brensocatib in bronchiectasis, sponsored by Insmed Incorporated. Primary endpoints: Area Under the Concentration Time Curve (AUC) of Brensocatib in Plasma at Day 14, AUC∞ Plasma Brensocatib/Plasma Total Radioactivity Ratio at Day 14 and 4 more. Started Aug 2021; status: completed.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT05652257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652257.